4//SEC Filing
TETRALOGIC PHARMACEUTICALS CORP 4
Accession 0000902664-16-008825
CIK 0001361248operating
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 6:31 PM ET
Size
13.5 KB
Accession
0000902664-16-008825
Insider Transaction Report
Form 4
Transactions
- Other
8% Senior Convertible Notes due 2019
2016-11-14→ 0 total(indirect: See footnote)→ Common Stock, $0.0001 par value ("Common Stock") (776,953 underlying) - Other
Preferred Stock
2016-11-14+1,463,594→ 1,463,594 total(indirect: See footnote)→ Common Stock (1,463,594 underlying) - Other
8% Senior Convertible Notes due 2024
2016-11-14(indirect: See footnote)Exp: 2024-06-15→ Common Stock (737,883 underlying)
Footnotes (6)
- [F1]The conversion rate is equal to 148.3019 shares of Common Stock per $1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately $6.74 per share of Common Stock), subject to adjustment upon the occurrence of certain specified events.
- [F2]On November 14, 2016, pursuant to the Exchange Agreement (as defined in the Schedule 13D filed by the Reporting Person on the date hereof), the notes are contingently convertible into Common Stock, subject to the Issuer's achievement of certain milestone or earn-out payments. The notes are not currently convertible. The Reporting Person expressly disclaims beneficial ownership of the shares of Common Stock underlying the notes.
- [F3]On November 14, 2016, pursuant to the Exchange Agreement, the Reporting Person agreed (i) to exchange $263,447 in aggregate principal amount of notes for 1,463,594 shares of Preferred Stock and (ii) to extend the maturity date to June 15, 2024 and modify the conversion terms of the Reporting Person's remaining $4,975,553 in aggregate principal amount of notes.
- [F4]Each share of Preferred Stock is initially convertible into one share of Common Stock, subject to adjustment as described in the Certificate of Designations for the Preferred Stock.
- [F5]The Preferred Stock is contingently convertible into Common Stock, subject to the Issuer's achievement of certain milestones payments and the deregistration of the Common Stock, as further described in the Certificate of Designations for the Preferred Stock. The Preferred Stock is not currently convertible. The Reporting Person expressly disclaims beneficial ownership of the shares of Common Stock underlying the Preferred Stock.
- [F6]The securities to which this filing relates are held directly by certain institutional and other client accounts for which the Reporting Person serves as the investment manager (the "Accounts"). The Reporting Person is the investment manager of the Accounts, and has been granted investment discretion over portfolio investments. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the Reporting Person's pecuniary interest therein.
Documents
Issuer
TETRALOGIC PHARMACEUTICALS CORP
CIK 0001361248
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001361248
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 6:31 PM ET
- Size
- 13.5 KB